Kura Oncology Inc Quick Ratio (KURA) starting from the third quarter 2026 to third quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Kura Oncology Inc   (NASDAQ: KURA)

Kura Oncology Inc 's Quick Ratio

KURA's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the third quarter 2026, Quick Ratio fell to 0.39 below Kura Oncology Inc average.

Within Major Pharmaceutical Preparations industry 384 other companies have achieved higher Quick Ratio than Kura Oncology Inc in third quarter 2026. While Quick Ratio total ranking in the third quarter 2026 has deteriorated compared to the prior quarter from 585 to 2461.

Explain Quick Ratio?
How much Cash & cash equivalents KURA´s has?
What are KURA´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/KURA/financial-strength
https://api.csimarket.com/api/v1/companies/KURA/fundamentals
https://api.csimarket.com/api/v1/companies/KURA/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
KURA Quick Ratio (Sep 30 2026)
Q3		 (Jun 30 2026)
Q2 		(Mar 31 2026)
Q1 		(Dec 31 2025)
Q4 		(Sep 30 2025)
Q3
Y / Y Current Liabilities Change 22.61 %
Y / Y Cash & cash equivalent Change -89.46 %
Quick Ratio MRQ 0.39
KURA's Total Ranking # 2461
Seq. Current Liabilities Change 25.84 %
Seq. Cash & cash equivalent Change -17.52 %



Quick Ratio third quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 385
Healthcare Sector # 717
Overall Market # 2461


Quick Ratio Statistics
High Average Low
34.81 13.47 0.03
(Dec 31 2015)  




Financial Statements
Kura Oncology Inc 's Current Liabilities $ 149 Millions Visit KURA's Balance sheet
Kura Oncology Inc 's Cash & cash equivalent $ 58 Millions Visit KURA's Balance sheet
Source of KURA's Sales Visit KURA's Sales by Geography


Cumulative Kura Oncology Inc 's Quick Ratio

KURA's Quick Ratio for the trailling 12 Months

KURA Quick Ratio

 (Sep 30 2026)
12 Months		 (Jun 30 2026)
12 Months 		(Mar 31 2026)
12 Months 		(Dec 31 2025)
12 Months 		(Sep 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth 22.28 %
Y / Y Cash & cash equivalent TTM Growth -46.37 %
Quick Ratio TTM 2.84
Total Ranking TTM # 1496
Seq. Current Liabilities TTM Growth 5.99 %
Seq. Cash & cash equivalent TTM Growth -26.32 %

Quick ratio ranking by company, industry and sector >> Back to KURA Financial Strength Comparisons >> Go to Compare KURA Quick Ratio to its Competitors

On the trailing twelve months basis Due to growth in Current Liabilities in the Q3 2026 to $148.73 millions, cumulative Quick Ratio decreased to 2.84 above the KURA average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 438 other companies have achieved higher Quick Ratio than Kura Oncology Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2026 from 3521 to 3992.

Explain Quick Ratio?
How much Cash & cash equivalents KURA´s has?
What are KURA´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 439
Healthcare Sector # 901
Within the Market #


trailing twelve months Quick Ratio Statistics
High Average Low
9.63 2.58 0.06
(Mar 31 2015)   (Mar 31 2013)




Companies with similar Quick Ratio in the quarter ending Sep 30 2026, within Major Pharmaceutical Preparations Industry Quick RatioSep 30 2026 MRQ Cash & cash equivalentSep 30 2026 MRQ Current Liabilities
Phathom Pharmaceuticals Inc   1.06 $ 184.558  Millions$ 174.902  Millions
Eton Pharmaceuticals Inc   1.03 $ 55.628  Millions$ 54.095  Millions
Oragenics Inc   1.02 $ 2.227  Millions$ 2.189  Millions
Geovax Labs Inc   1.01 $ 2.151  Millions$ 2.135  Millions
Akebia Therapeutics Inc   0.98 $ 159.254  Millions$ 162.349  Millions
Acadia Pharmaceuticals Inc   0.97 $ 322.365  Millions$ 332.217  Millions
Alkermes Plc   0.97 $ 631.314  Millions$ 651.933  Millions
Imunon Inc   0.95 $ 4.039  Millions$ 4.239  Millions
Geron Corporation  0.94 $ 69.794  Millions$ 74.248  Millions
Mirum Pharmaceuticals Inc   0.86 $ 243.188  Millions$ 283.080  Millions
Amphastar Pharmaceuticals Inc   0.86 $ 262.786  Millions$ 306.303  Millions
Aclaris Therapeutics Inc   0.84 $ 20.394  Millions$ 24.222  Millions
Seres Therapeutics Inc   0.84 $ 17.528  Millions$ 20.893  Millions
Jazz Pharmaceuticals Plc  0.80 $ 2,036.400  Millions$ 2,540.300  Millions
Zomedica Corp   0.80 $ 7.281  Millions$ 9.096  Millions
Pfizer Inc  0.79 $ 25,140.000  Millions$ 31,726.000  Millions
Xencor Inc  0.78 $ 59.622  Millions$ 76.266  Millions
Janux Therapeutics Inc   0.77 $ 41.818  Millions$ 54.247  Millions
Arcus Biosciences Inc   0.76 $ 151.000  Millions$ 199.000  Millions
Ligand Pharmaceuticals Incorporated  0.75 $ 374.303  Millions$ 500.569  Millions
Alumis inc   0.73 $ 57.691  Millions$ 79.405  Millions
Rockwell Medical inc   0.71 $ 10.750  Millions$ 15.073  Millions
Ionis Pharmaceuticals Inc   0.68 $ 296.303  Millions$ 435.292  Millions
Liquidia Corporation  0.68 $ 396.091  Millions$ 585.397  Millions
Bristol myers Squibb Company  0.67 $ 12,581.000  Millions$ 18,753.000  Millions
Harrow Inc   0.66 $ 75.336  Millions$ 114.224  Millions
Supernus Pharmaceuticals inc   0.62 $ 176.171  Millions$ 285.397  Millions
Axsome Therapeutics Inc   0.62 $ 313.859  Millions$ 509.719  Millions
Travere Therapeutics Inc   0.59 $ 123.542  Millions$ 210.912  Millions
Clene Inc   0.58 $ 9.887  Millions$ 17.114  Millions

Date modified: 2026-11-11T18:29:43+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.